Goldline Pharmaceutical Limited (BSE: 544759)
Health Care · Pharmaceuticals · IN
Rs40.09
-2.79% today · -29.4% 1Y
Goldline Pharmaceutical Limited (BSE: 544759) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $4.03M.
Over the last twelve months the share price has lost 29.4%, trading between 33.00 and 60.00.
Tweenvest scores Goldline Pharmaceutical Limited across four factors: quality 65/100, growth 80/100. Its strongest factor is growth.
544759 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $4.03M
- Revenue (TTM)
- $3.33M
- P/E
- 6.72
- EPS
- 5.97
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- Rs60.00
- 52-week low
- Rs33.00
- Avg volume (3M)
- —
- Shares outstanding
- 9.60M
- Employees
- —
- Next earnings
- —
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $368.80B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.